224 related articles for article (PubMed ID: 18982740)
21. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999.
Thorpe LE; Ouellet LJ; Levy JR; Williams IT; Monterroso ER
J Infect Dis; 2000 Dec; 182(6):1588-94. PubMed ID: 11069228
[TBL] [Abstract][Full Text] [Related]
23. Differentiated risk behaviour for HIV and hepatitis among injecting drug users (IDUs).
Nordén L; Lidman C
Scand J Infect Dis; 2005; 37(6-7):493-6. PubMed ID: 16012010
[TBL] [Abstract][Full Text] [Related]
24. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
[TBL] [Abstract][Full Text] [Related]
26. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
27. [Prevalence of antibody to hepatitis C virus in 177 drug addicts].
Ye S
Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Feb; 14(1):45-8. PubMed ID: 8389248
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C virus infection among noninjecting drug users in New York City.
Koblin BA; Factor SH; Wu Y; Vlahov D
J Med Virol; 2003 Jul; 70(3):387-90. PubMed ID: 12767001
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of human immunodeficiency virus and its association with hepatitis B, C, and D virus infections among incarcerated male substance abusers in Taiwan.
Chu FY; Chiang SC; Su FH; Chang YY; Cheng SH
J Med Virol; 2009 Jun; 81(6):973-8. PubMed ID: 19382252
[TBL] [Abstract][Full Text] [Related]
30. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China.
Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS
PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888
[TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection.
Dalgard O; Egeland A; Skaug K; Vilimas K; Steen T
Hepatology; 2004 Jan; 39(1):74-80. PubMed ID: 14752825
[TBL] [Abstract][Full Text] [Related]
32. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users.
Vidal-Trecan GM; Varescon-Pousson I; Gagnière B; Tcherny- Lessenot S; Madariaga E; Boissonnas A
Ann Med Interne (Paris); 2002 Jun; 153(4):219-25. PubMed ID: 12218887
[TBL] [Abstract][Full Text] [Related]
33. Seroprevalence, risk factors, and hepatitis C virus genotypes in groups with high-risk sexual behavior in Croatia.
Cavlek TV; Margan IG; Lepej SZ; Kolaric B; Vince A
J Med Virol; 2009 Aug; 81(8):1348-53. PubMed ID: 19551819
[TBL] [Abstract][Full Text] [Related]
34. Measuring risk of HIV and HCV among injecting drug users in the Russian Federation.
Platt L; Sutton AJ; Vickerman P; Koshkina E; Maximova S; Latishevskaya N; Hickman M; Bonell C; Parry J; Rhodes T
Eur J Public Health; 2009 Aug; 19(4):428-33. PubMed ID: 19349288
[TBL] [Abstract][Full Text] [Related]
35. Injecting drug users' understanding of hepatitis C.
O'Brien S; Day C; Black E; Dolan K
Addict Behav; 2008 Dec; 33(12):1602-5. PubMed ID: 18762384
[TBL] [Abstract][Full Text] [Related]
36. The impact of injecting drug use status on hepatitis C-related referral and treatment.
Stoové MA; Gifford SM; Dore GJ
Drug Alcohol Depend; 2005 Jan; 77(1):81-6. PubMed ID: 15607844
[TBL] [Abstract][Full Text] [Related]
37. A longitudinal investigation into excess risk for blood-borne infection among young injection drug users (IUDs).
Miller CL; Strathdee SA; Li K; Kerr T; Wood E
Am J Drug Alcohol Abuse; 2007; 33(4):527-36. PubMed ID: 17668338
[TBL] [Abstract][Full Text] [Related]
38. Trends in HCV prevalence, risk factors and distribution of viral genotypes in injecting drug users: findings from two cross-sectional studies.
Oliveira ML; Yoshida CF; Telles PR; Hacker MA; Oliveira SA; Miguel JC; do O KM; Bastos FI
Epidemiol Infect; 2009 Jul; 137(7):970-9. PubMed ID: 19144250
[TBL] [Abstract][Full Text] [Related]
39. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.
Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS
Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran.
Zamani S; Ichikawa S; Nassirimanesh B; Vazirian M; Ichikawa K; Gouya MM; Afshar P; Ono-Kihara M; Ravari SM; Kihara M
Int J Drug Policy; 2007 Oct; 18(5):359-63. PubMed ID: 17854723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
